NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.
|Videos|April 30, 2019
A 58-Year-Old Woman with Polycythemia Vera
A 58-Year-Old Woman with Polycythemia Vera
Advertisement
Case: 58-Year-Old Woman Diagnosed With Polycythemia Vera
November 2018
- A 58-year old woman presents to PCP complaining of abdominal pain, dizziness and headaches
- PE: BP 140/85; Splenomegaly ~6 cm below left costal margin
- PMH: No prior history of thrombosis
- Lab values:
- HGB: 17.1 g/dL
- Hct: .50 L/L
- RBC: 71 x 1012/L
- WBC: 13.2 x 109/L
- Serum EPO: 4.1 mU/mL
- Bone Marrow Biopsy: Erythroid hyperplasia
- Cytogenetics: JAK-V617Fmutation
Advertisement
Related to this article
The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward
3
Tovecimig Submission for Biliary Tract Cancer Is Proceeding Despite FDA Request for New Trial
4
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
5